Drugs / Nicotine Patch
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02162849 | Dec 2015 → Feb 2028 expected | nicotine dependence | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-22 | Pfizer | Results CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet pfizer.com ↗
The authors concluded that the trial did not show a significant increase in the incidence of the composite primary safety endpoint of serious neuropsychiatric adverse events with CHANTIX/CHAMPIX or bupropion compared to placebo and nicotine patch. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-22 | Pfizer | CHANTIX®/CHAMPIX® (varenicline) Results from the Largest Global Clinical Trial of Smoking Cessation Medicines Published in The Lancet pfizer.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicotine Patch | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02162849 ↗ |
| Route | Topical | “You should apply the nicotine/placebo patch to the upper arm.” NCT02162849 ↗ |